Flamel Technologies Sells Development and Manufacturing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Flamel Technologies Sells Development and Manufacturing Facility in Pessac, France to Recipharm AB

LYON, FRANCE--(Marketwired - Nov 28, 2014) -  Flamel Technologies ( NASDAQ : FLML ) announced today that it has entered into an agreement to divest its development and manufacturing facility located in Pessac, France, to Recipharm AB. Under the agreement, Recipharm will pay Flamel EUR 10.6 million and make an investment of EUR 10.5 million in Flamel's stock upon the closing of deal at a purchase price equal to the trailing 20-day average price. This new partnership allows Flamel to retain access to the development and manufacturing capabilities of Pessac and gain the use of any of Recipharm's other facilities for the development or manufacture of their proprietary pipeline if needed. The Pessac facility is not currently used for the production of Flamel finished products and Flamel intends to continue to outsource to third party contract manufacturing companies like Recipharm.

"Flamel's primary objective is the development of products using the company's proprietary drug delivery platforms. The sale of the Pessac facility frees Flamel from the time-consuming task of running a contract development manufacturing facility," said Michael S. Anderson, Chief Executive Officer. "This sale allows us to continue to call on the Pessac facility for technical aspects of development of our proprietary products using our current drug delivery technologies and the option to utilize Recipharm's commercial manufacturing capabilities elsewhere. Given Recipharm's expertise, the investment in Flamel's stock is a welcome endorsement of Flamel's anticipated success moving forward."

Highlights:

  • The purchase price for the Pessac facility and its assets is EUR 10.6 million.
  • In a separate transaction, Recipharm AB will also make an investment of EUR 10.5 million into Flamel's stock upon the closing of deal at a purchase price equal to the trailing 20-day average price.
  • Flamel and Recipharm will enter into a 5 year service agreement.
  • Included in the sale of the facility is the royalty contract for Coreg CR with Glaxo SmithKline.
  • Recipharm has an option to negotiate with Flamel for the European rights to any product that Flamel plans to license for sale in the European market.
  • Recipharm and Flamel have agreed to negotiate a contract with the intention of further enhancing the economic benefits to both companies whereby Recipharm will incorporate Flamel's drug delivery technologies in its contract development business.

The Pessac facility is located in Bordeaux, France. It is a modern, fully compliant CMP (FDA and ANSM approved) facility for the development and manufacturing of pharmaceuticals. The facility currently manufactures Flamel's Medusa and Micropump proprietary drug delivery technologies. It is equipped with three spray-coating machines, warehousing, analytical and Quality Control laboratories, and equipment for polymer synthesis.

The closing of the transaction is expected to occur before year end 2014, and there are no material conditions to the closing.

About Recipharm - Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry based in Sweden employing some 2,100 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma through to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.2 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com . 

About Flamel Technologies - Flamel Technologies SA's ( NASDAQ : FLML ) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The Company markets Bloxiverz® (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and manufactures Micropump-based microparticles under FDA-audited GMP guidelines for Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes chemical and biological drugs formulated with its Micropump® (and its applications to the development of liquid formulations LiquiTime® and of abuse-deterrent formulations Trigger Lock™) and Medusa™ proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and manufacturing facilities in Pessac, France. Additional information may be found at www.flamel.com . 

Safe Harbor: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals and projections regarding financial results, product developments and technology platforms. All statements that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estimate," "plan," "will," "may," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that the launch of Bloxiverz ® and Vazculep™ will not be as successful as anticipated; our ability to bring other R&D projects of the former Éclat Pharmaceuticals to market may be unsuccessful; clinical trial results may not be positive or our partners may decide not to move forward; products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements; products in development may not achieve market acceptance; competitive products and pricing may hinder our commercial opportunities; we may not be successful in identifying and pursuing opportunities to develop our own product portfolio using Flamel's technology; and the risks associated with our reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on Form 20-F for the year ended December 31, 2013 that has been filed with the Securities and Exchange Commission (SEC). All forward-looking statements included in this release are based on information available at the time of the release. We undertake no ligation to update or alter our forward-looking statements as a result of new information, future events or otherwise.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 67

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 33

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 44

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 0

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 25

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading

Top 5 Most Recently Viewed Articles

Cypherpunk Technologies Boosts Zcash Holdings Significantly Year-Over-Year

Updated Category News Views 108

Cypherpunk Technologies Expands Zcash Accumulation CAMBRIDGE, Mass. — Cypherpunk Technologies Inc. (Nasdaq: CYPH), a company deeply engaged in privacy technology, has recently accelerated its efforts to accumulate Zcash, significantly boosting its treasury holdings. This move reflects their strategic commitment to enhancing their corporate asset portfolio and addressing...

Continue Reading
Insights from Access LIVE: The Future of Beverage Leadership

Updated Category News Views 253

Insights from Access LIVE: The Future of Beverage Leadership Leaders from the nation's largest distributors convened to share their insights on innovation, growth, and the future of the beverage alcohol industry. The session, known as "Wholesaler Power Hour — Market Drivers: Wholesale Leaders Blazing a Path to Success," took place on the LIVE Stage at Access LIVE 2025,...

Continue Reading
Understanding Microsoft's Competitive Edge in the Software Sector

Updated Category News Views 211

Dynamic Insights into Microsoft and Its Competitors In the rapidly evolving business landscape, a thorough examination of companies is vital for investors and enthusiasts alike. This article delves into a detailed comparative analysis of Microsoft (NASDAQ: MSFT) relative to its main competitors within the software industry. By evaluating essential financial metrics,...

Continue Reading
The Transformative Financial Journey of Pan American Silver Stock

Updated Category News Views 154

The Impact of Long-Term Investment in Pan American Silver Investing in stocks is often seen as a journey, and Pan American Silver (NYSE: PAAS) stands as a shining example of how patience can yield extraordinary rewards over the years. Over the last decade, Pan American Silver has surpassed market performance, boasting an annualized return of 22.95%, which is significantly...

Continue Reading
Linc Housing Initiates Construction of 90 Affordable Units

Updated Category News Views 219

Linc Housing Begins Construction on New Affordable Homes In a promising development for families in need, Linc Housing has commenced the construction of three new affordable apartment communities. This initiative will create 90 new homes specifically designed for low-income individuals and families. The timing could not be more critical, as communities grapple with an...

Continue Reading